Celltrion To Begin Denosumab Trials Within Days
Plans To Complete Trials Before Prolia’s Patent Expires
Celltrion has announced plans to proceed to Phase I clinical trials of its Prolia/Xgeva (denosumab) biosimilar candidate. The company is also working on biosimilar versions of bevacizumab, omalizumab and ustekinumab for both Europe and the US.
You may also be interested in...
Australia’s NeuClone has revealed further details of its pipeline, offering an update that includes a glimpse at two further biosimilar projects that are in active development.
South Korea’s Celltrion has partnered with oral drug delivery specialist Intract Pharma for the formulation of oral infliximab for the treatment of inflammatory bowel disease. Celltrion has also reported year-on-year and quarter-on-quarter growth in sales, along with plans to grow in the US market.
Hungary’s Gedeon Richter is continuing efforts to bring multiple biosimilars to market, while reaping the benefits of the biosimilar to Eli Lilly’s Forsteo (teriparatide) in the EU and Japan. Management discussed Richter’s achievements on the company’s first-half earnings call, while also commenting on how markets have reacted to the COVID-19 pandemic.